Forest/Lipha Acamprosate Subgroup Analysis Of EU Data Suggested By Cmte.
Executive Summary
A subgroup analysis of European trial data for Forest/Lipha's acamprosate would help clarify whether trends seen in certain U.S. clinical trial subpopulations are meaningful, FDA's Psychopharmacologic Drugs Advisory Committee suggested May 10